UK Rare Disease Clinical Trials Market Size & Outlook

The rare disease clinical trials market in UK is expected to reach a projected revenue of US$ 900.4 million by 2030. A compound annual growth rate of 10.7% is expected of UK rare disease clinical trials market from 2024 to 2030.
Revenue, 2023 (US$M)
$440.6
Forecast, 2030 (US$M)
$900.4
CAGR, 2024 - 2030
10.7%
Report Coverage
UK

UK rare disease clinical trials market, 2018-2030 (US$M)

UK

UK rare disease clinical trials market highlights

  • The UK rare disease clinical trials market generated a revenue of USD 440.6 million in 2023 and is expected to reach USD 900.4 million by 2030.
  • The UK market is expected to grow at a CAGR of 10.7% from 2024 to 2030.
  • In terms of segment, phase ii was the largest revenue generating phase in 2023.
  • Phase III is the most lucrative phase segment registering the fastest growth during the forecast period.

Rare disease clinical trials market data book summary

Market revenue in 2023USD 440.6 million
Market revenue in 2030USD 900.4 million
Growth rate10.7% (CAGR from 2023 to 2030)
Largest segmentPhase ii
Fastest growing segmentPhase III
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationPhase I, Phase II, Phase III, Phase IV
Key market players worldwideTakeda Pharmaceutical Co Ltd, Roche Holding AG ADR, Pfizer Inc, AstraZeneca PLC, Novartis AG ADR, Labcorp Holdings Inc, IQVIA Holdings Inc, Charles River Laboratories International Inc, Icon PLC, PAREXEL

Other key industry trends

  • In terms of revenue, UK accounted for 5.3% of the global rare disease clinical trials market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, France rare disease clinical trials market is projected to lead the regional market in terms of revenue in 2030.
  • UK is the fastest growing regional market in Europe and is projected to reach USD 900.4 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Rare Disease Clinical Trials Market Scope

Rare disease clinical trials market segmentation & scope
Phase I
Phase II
Phase III
Phase IV
Others
Interventional trials
Observational trials
Expanded access trials
Cardiovascular Disorders
Neurological Disorders
Infectious Disease
Genetic Disorders
Autoimmune and Inflammation
Hematologic Disorders
Musculoskeletal Disorders
Others

Rare Disease Clinical Trials Market Companies

Name Profile # Employees HQ Website

UK rare disease clinical trials market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare disease clinical trials market will help companies and investors design strategic landscapes.


Phase ii was the largest segment with a revenue share of 42.65% in 2023. Horizon Databook has segmented the UK rare disease clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.


  • UK Rare Disease Clinical Trials Phase Outlook (Revenue, USD Million, 2018-2030)
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
    • Others
  • UK Rare Disease Clinical Trials Study Design Outlook (Revenue, USD Million, 2018-2030)
    • Interventional trials
    • Observational trials
    • Expanded access trials
  • UK Rare Disease Clinical Trials Therapeutic Area Outlook (Revenue, USD Million, 2018-2030)
    • Cardiovascular Disorders
    • Neurological Disorders
    • Infectious Disease
    • Genetic Disorders
    • Autoimmune and Inflammation
    • Hematologic Disorders
    • Musculoskeletal Disorders
    • Others

Reasons to subscribe to UK rare disease clinical trials market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of UK rare disease clinical trials market databook

  • Our clientele includes a mix of rare disease clinical trials market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the UK rare disease clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into UK rare disease clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

UK rare disease clinical trials market size, by phase, 2018-2030 (US$M)

UK Rare Disease Clinical Trials Market Outlook Share, 2023 & 2030 (US$M)

UK rare disease clinical trials market size, by phase, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more